|
By Brian Wilson, Contributor
|
|
Thursday, 06 September 2012 07:04 |
 Forest Laboratories (NYSE: FRX) is a ~$9 billion diversified pharmaceutical company that is heavily owned by investment managers. The company has been providing steady revenue growth for years and has an ever-expanding R&D budget, and has been attracting attention from the strength of the company's financial data.
|
|
Read more...
|
|
By Scott Matusow, Contributor
|
|
Wednesday, 05 September 2012 07:21 |
 Trading Biopharmaceuticals through a catalyst event can prove to be very rewarding for investors if the outcome from the company's catalyst is positive news.
|
|
Read more...
|
|
By Brian Wilson
|
|
Tuesday, 04 September 2012 03:36 |
|
Alexza Pharmaceuticals (NASDAQ: ALXA) is a very small company by market capitalization (worth about $50.7 million based on current outstanding shares), and it seems to have a difficult time with its flagship drug ADASUVE (also known as staccato loxapine).
|
|
Read more...
|
|
By M.E.Garza
|
|
Friday, 31 August 2012 06:11 |
 Managing Director Greg Wade of Wedbush Securities doesn't use a cookie-cutter approach to picking biotechnology stocks. He directs investors to companies with strong science, well-executed clinical studies and data that points toward future success.
|
|
Read more...
|
|
By M.E.Garza
|
|
Wednesday, 29 August 2012 04:26 |
On Tuesday afternoon, we tweeted to our followers that it might not be a bad idea to pick up some shares of Medgenics, Inc. (AMEX:MDGN) (AIM: MEDU, MEDG), particularly given the recent buzz about the firm's anticipated hepatitis pipeline development milestone.
|
|
Read more...
|
|
By Michael Morhamus
|
|
Tuesday, 28 August 2012 09:29 |
|
Pulmonary arterial hypertension (PAH) is a chronic syndrome characterized by abnormally high pressure in arteries leading from the heart to the lungs that cause dizziness, fatigue, and shortness of breath.
|
|
Read more...
|
|
By George S. Mack of the Life Sciences Report
|
|
Friday, 24 August 2012 05:12 |
|
Chen Lin is a well-known expert junior metals and energy investor, but he has found compelling reasons to diversify into biotechnology.
|
|
Read more...
|
|
By Brian Wilson
|
|
Thursday, 23 August 2012 06:01 |
 Opko Health (NYSE: OPK) is an up-and-coming medical products company that is often the focus of speculation solely because of its CEO Dr. Phillip Frost, who is holding 128,490,000 shares of the company, which represents about 43% of the company's shares (not counting dilution).
|
|
Read more...
|
|
By M.E.Garza
|
|
Wednesday, 22 August 2012 03:40 |
|
The latest battle between longs and naked shorts may present traders another opportunity to benefit form being in the right trade at the right time.
|
|
Read more...
|
|
By Brian Wilson, Contributor
|
|
Tuesday, 21 August 2012 04:06 |
|
Shares of the medical device company Mako Surgical Corp. (NASDAQ: MAKO) have seen a steady recovery after the company released quarterly results (for Q2 2012) in early August. Although recent gains have been significant, they are still nothing compared to the drop we saw on July 10th where the company initially hinted that the second quarter was not going to produce the results that investors were hoping for.
|
|
Read more...
|
|
|
<< Start < Prev 51 52 53 54 55 56 Next > End >>
|
|
Page 52 of 56 |
